

DO NOT ENTER
EGS
08/15/2008

In the Claims

1-34. (canceled)

35. (currently amended) An isolated polypeptide consisting of:

- a) amino acids 94-124 of human OX40 ligand (OX40L);
- b) amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said polypeptide contains amino acids 107-111 of human OX40L and said polypeptide binds to the OX40 receptor (OX40R);
- c) between 5 and 10 contiguous amino acids of human OX40L, wherein said polypeptide contains amino acids 107-111 of OX40L and binds to OX40R;
- d) amino acids 107-116 or 107-111 of human OX40L;
- e) an active mutant of a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R;
- f) a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to:
 - i) a peptide consisting of amino acids 94-124 of human OX40L;
 - ii) a peptide consisting of amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said peptide contains amino acids 107-111 and said fusion polypeptide binds OX40R;
 - iii) an amino acid sequence of between 5 and 10 contiguous amino acids of human OX40L that includes amino acids 107-111 of OX40L and said fusion polypeptide binds to OX40R;
 - iv) a peptide consisting of amino acids 107-116 or 107-111 of human OX40L; or
- g) a derivative of a), b), c), d), e) or f).

36. (previously presented) The isolated polypeptide according to claim 35, wherein said fusion polypeptide or peptide comprises the amino acid sequence belonging to one or more of the following protein sequences: membrane-bound proteins, extracellular domains of membrane-bound protein, immunoglobulin constant region, multimerization domains, extracellular proteins, signal peptide-containing proteins, export signal-containing proteins.

37. (previously presented) The isolated polypeptide according to claim 35, further comprising a molecule selected from the group consisting of radioactive labels, biotin, fluorescent labels, cytotoxic agents, and drug delivery agents.

38. (canceled)

39. (currently amended) An isolated peptide, peptide mimetic, or a non-peptide mimetic of amino acids 107-116 or 107-111 of human OX40L.

40-56. (canceled)

57. (previously presented) The isolated polypeptide according to claim 35, wherein said polypeptide consists of amino acids 94-124 of human OX40L.

58. (previously presented) The isolated polypeptide according to claim 35, wherein said polypeptide consists of amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said polypeptide contains amino acids 107-111 of human OX40L and said polypeptide binds to the OX40 receptor (OX40R).

59. (currently amended) The isolated polypeptide according to claim 35, wherein said polypeptide consists of between 5 and 10 contiguous amino acids of human OX40L, contains amino acids 107-111 of OX40L and binds to OX40R.

60. (previously presented) The isolated polypeptide according to claim 35, wherein said polypeptide consists of amino acids 107-116 of human OX40L.

61. (previously presented) The isolated polypeptide according to claim 35, wherein said polypeptide consists of amino acids 107-111 of human OX40L.

62. (previously presented) The isolated polypeptide according to claim 35, wherein said polypeptide consists of an active mutant of a), b), c) or d), wherein three or fewer amino acids are conservatively substituted and said active mutant binds to OX40R.

63. (previously presented) The isolated polypeptide according to claim 35, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 94-124 of human OX40L.

64. (currently amended) The isolated polypeptide according to claim 35, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said peptide contains amino acids 107-111 and said fusion polypeptide binds OX40R.

65. (currently amended) The isolated polypeptide according to claim 35, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to an amino acid sequence of between 5 and 10 contiguous amino acids of human OX40L that includes amino acids 107-111 of OX40L and said fusion polypeptide binds to OX40R.

66. (currently amended) The isolated polypeptide according to claim 35, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 107-116 of human OX40L.

67. (previously presented) The isolated polypeptide according to claim 35, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 107-111 of human OX40L.

68. (previously presented) The isolated polypeptide according to claim 35, wherein said polypeptide is a derivative of a), b), c), d), e) or f).

69. (currently amended) A composition comprising a pharmaceutically acceptable carrier, excipient, stabilizer, diluent, or combination thereof and a polypeptide consisting of:

- a) amino acids 94-124 of human OX40 ligand (OX40L);
- b) amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said polypeptide contains amino acids 107-111 of human OX40L and said polypeptide binds to the OX40 receptor (OX40R);
- c) between 5 and 10 contiguous amino acids of human OX40L, wherein said polypeptide contains amino acids 107-111 of human OX40L and binds to OX40R;
- d) amino acids 107-116 or 107-111 of human OX40L;
- e) an active mutant of a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R;
- f) a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to:
 - i) a peptide consisting of amino acids 94-124 of human OX40L;
 - ii) a peptide consisting of amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said peptide contains amino acids 107-111 and said fusion polypeptide binds OX40R;
 - iii) an amino acid sequence of between 5 and 10 contiguous amino acids of human OX40L that includes amino acids 107-111 of human OX40L and said fusion polypeptide binds to OX40R;

- iv) a peptide consisting of amino acids 107-116 or 107-111 of human OX40L; or
- g) a derivative of a), b), c), d), e) or f).

70. (previously presented) The composition according to claim 68, wherein said polypeptide consists of amino acids 94-124 of human OX40L.

71. (previously presented) The composition according to claim 68, wherein said polypeptide consists of amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said polypeptide contains amino acids 107-111 of human OX40L and said polypeptide binds to the OX40 receptor (OX40R).

72. (currently amended) The composition according to claim 68, wherein said polypeptide consists of between 5 and 10 contiguous amino acids of human OX40L, contains amino acids 107-111 of human OX40L and binds to OX40R.

73. (previously presented) The composition according to claim 68, wherein said polypeptide consists of amino acids 107-116 of human OX40L.

74. (previously presented) The composition according to claim 68, wherein said polypeptide consists of amino acids 107-111 of human OX40L.

75. (previously presented) The composition according to claim 68, wherein said polypeptide consists of an active mutant of a), b), c) or d), wherein three or fewer amino acids are conservatively substituted and said active mutant binds to OX40R.

76. (previously presented) The composition according to claim 68, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 94-124 of human OX40L.

77. (currently amended) The composition according to claim 68, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said peptide contains amino acids 107-111 and said fusion polypeptide binds OX40R.

78. (currently amended) The composition according to claim 68, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to an amino acid sequence of between 5 and 10 contiguous amino acids of human OX40L that includes amino acids 107-111 of human OX40L and said fusion polypeptide binds to OX40R.

79. (currently amended) The composition according to claim 68, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 107-116 of human OX40L.

80. (previously presented) The composition according to claim 68, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 107-111 of human OX40L.

81. (previously presented) The composition according to claim 68, wherein said polypeptide is a derivative of a), b), c), d), e) or f).

82. (currently amended) A composition of matter comprising a solid support and a polypeptide consisting of:

- a) amino acids 94-124 of human OX40 ligand (OX40L);
- b) amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said polypeptide contains amino acids 107-111 of human OX40L and said polypeptide binds to the OX40 receptor (OX40R);

- c) between 5 and 10 contiguous amino acids of human OX40L, wherein said polypeptide contains amino acids 107-111 of human OX40L and binds to OX40R;
- d) amino acids 107-116 or 107-111 of human OX40L;
- e) an active mutant of a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R;
- f) a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to:
 - i) a peptide consisting of amino acids 94-124 of human OX40L;
 - ii) a peptide consisting of amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said peptide contains amino acids 107-111 and said fusion polypeptide binds to OX40R;
 - iii) an amino acid sequence of between 5 and 10 contiguous amino acids of human OX40L that includes amino acids 107-111 of human OX40L and said fusion polypeptide binds to OX40R;
 - iv) a peptide consisting of amino acids 107-116 or 107-111 of human OX40L; or
- g) a derivative of a), b), c), d), e) or f).

83. (previously presented) The composition of matter according to claim 82, wherein said polypeptide consists of amino acids 94-124 of human OX40L.

84. (previously presented) The composition of matter according to claim 82, wherein said polypeptide consists of amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said polypeptide contains amino acids 107-111 of human OX40L and said polypeptide binds to the OX40 receptor (OX40R).

85. (currently amended) The composition of matter according to claim 82, wherein said polypeptide consists of between 5 and 10 contiguous amino acids of human OX40L, contains amino acids 107-111 of human OX40L and binds to OX40R.

86. (previously presented) The composition of matter according to claim 82, wherein said polypeptide consists of amino acids 107-116 of human OX40L.

87. (previously presented) The composition of matter according to claim 82, wherein said polypeptide consists of amino acids 107-111 of human OX40L.

88. (previously presented) The composition of matter according to claim 82, wherein said polypeptide consists of an active mutant of a), b), c) or d), wherein three or fewer amino acids are conservatively substituted and said active mutant binds to OX40R.

89. (previously presented) The composition of matter according to claim 82, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 94-124 of human OX40L.

90. (currently amended) The composition of matter according to claim 82, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 94-124 of human OX40L, wherein one or more amino acids have been deleted, said peptide contains amino acids 107-111 and said fusion polypeptide binds OX40R.

91. (currently amended) The composition of matter according to claim 82, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to an amino acid sequence of between 5 and 10 contiguous amino acids of human OX40L that includes amino acids 107-111 of human OX40L and said fusion polypeptide binds to OX40R.

92. (currently amended) The composition of matter according to claim 82, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 107-116 of human OX40L.

93. (previously presented) The composition of matter according to claim 82, wherein said polypeptide is a fusion polypeptide or peptide comprising a protein sequence other than human OX40L fused to a peptide consisting of amino acids 107-111 of human OX40L.

94. (previously presented) The composition of matter according to claim 82, wherein said polypeptide is a derivative of a), b), c), d), e) or f).